Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe and approval of new CE Marking for Microdacyn60® Eye Care

PETALUMA, Calif.--(BUSINESS WIRE)-- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Marking (Conformité Européenne) for its Microdacyn60® Eye Care based on Sonoma’s patented Microcyn® Technology.

The formulation, marketed in the United States as Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene solution, is a safe and efficacious method to keep areas around the eye and eyelids/eyelashes clean and remove foreign materials. Sonoma’s performance-stabilized hypochlorous acid (HOCl), which is at the heart of Acuicyn and Microdacyn60® Eye Care, can be used safely around eyes, ears, nose and mouth without concerns about toxicity or stinging.

Sonoma is also pleased to announce that it has agreed on a new 10-year license, distribution and supply agreement with its distribution partner Brill International S.L. to market the eye care product under the private label Ocudox™ in the European markets of Italy, Germany, Spain, Portugal and the United Kingdom, subject to Brill meeting certain annual minimum purchase requirements. Previously, Sonoma’s highly successful partnership with Brill covered only the Spanish and Portugese markets.

“We are pleased by the reaffirmation of our patented Microcyn Technology products by the European Union,” said Amy Trombly, CEO of Sonoma. She continued “Our powerful Microcyn® technology has many applications treating a wide range of symptoms and conditions. We are excited to take our partnership with Brill to the next level and increase our eye care presence in Europe.”

“We are thrilled to partner with Sonoma to expand marketing of Ocudox to other important European markets,” said Dr. Jordi Martínez Rotllan, director at Brill International, S.L. “In the past two years, we have had incredible success selling Ocudox in Spain and Portugal being the reference product in the management of blepharitis and the only hypochlorous acid ophthalmic product in the market. The new CE marking will help to open these markets to this very safe and effective eye formulation and to achieve increased sales in the extended territories.”

Ocudox is expected to become available in Italy, Germany and the United Kingdom in a phased rollout over the next 12 months. For more information or to order, visit

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruretic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogensand breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 53 countries worldwide and the company actively seeks new distribution partners. The company has offices in Petaluma, California and Woodstock, Georgia, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact

About Brill International S.L.

Brill International is company related to Brill Pharma Laboratories, a pharmaceutical company based in Barcelona, Spain with additional offices in London, Lisbon, Frankfurt and Mumbay. The company researches, develops, produces, licenses and commercializes ophthalmology products with the purpose of improving people’s health and well-being. Brill Pharma has achieved the leadership in the ocular surface market being also the fastest growing pharmaceutical company in Spain and Portugal. BRILL PHARMA laboratories is formed by a team of 150 professionals, most of them in the commercial area being the largest salesforce in ophthalmology in Spain. Our team is continuously trained on our product lines to ensure better advice for pharmacies and the medical community. More information can be found at

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “reduce,” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™, Acuicyn™, Microcyn® and Microdacyn60® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Grant Edwards
Sonoma Pharmaceuticals, Inc.

Source: Sonoma Pharmaceuticals, Inc.